1,720,984 research outputs found
Clinical efficacy and tolerance of nabumetone in articular and non-articular rheumatic disorders: personal experience during 12 weeks of treatment.
No full textBACKGROUND: We evaluated the clinical efficacy and the tolerance of Nabumetone (N), in comparison with a pool of non-steroidal anti-inflammatory drugs (NSAIDs), in a cohort of patients affected by rheumatoid arthritis, osteoarthritis, non-articular rheumatisms and primary fibromyalgic syndrome.
METHODS: One hundred and seventy patients were observed in an open-non randomized study. The patients have been recruited alternatively and subdivided into two groups: 84 patients that received N and 86 patients that received one of the other NSAIDs. All the patients affected by rheumatoid arthritis received a disease-modifying anti-rheumatic drug (OH-chloroquine, d-penicillamine, auranofin, cyclosporine-A); while benzodiazepines are administered in the patients suffering from primary fibromyalgic syndrome. A follow-up not inferior to 12 consecutive weeks was realized and the following clinical parameters were studied: spontaneous pain, provoked pain, pain on active movement, pain on passive movement, pain at rising, pain at bed time, morning stiffness, limited joint mobility, number of tender points, number of affected joints and number of swollen joints. All the patients were monitored for hematological, biochemical, urinary and clotting tests.
RESULTS: The results revealed an excellent tolerability of nabumetone with a clinical efficacy not inferior to the NSAIDs' pool. Moreover, the number of drop-outs in the N-group were significantly inferior in comparison to the NSAIDs'-pool group.
CONCLUSIONS: We conclude that N can be considered as effective as other NSAIDs. Moreover it seems to be better tolerated that the other NSAIDs utilized in our study
Cardiac muscle antibodies in diabetes mellitus and dilated cardiomyopathy: preliminary results.
No full textQualità della vita nell'artrite psoriasica. Proposta di un questionario per la valutazione
No full textCaratteristiche metaboliche di pazienti con polientesopatia iperostosante dismetabolica affetti da obesità, diabete mellito di tipo 1 e tipo 2 e intolleranza agli idrati di carbonio.
No full textHydromorphone does not influence the immune response in patients affected by chronic pain.
No full textHydromorphone (HMP) is a semisynthetic opioid that has been widely used over many years in the treatment of chronic moderate-severe pain. A number of studies have demonstrated the use of HMP in patients with cancer pain as safe and affective, and more recently HMP has been also utilised in the treatment of chronic degenerative pain (CDP). Then, some opioids are able to influence several immune parameters. Aim of our study was to assess HMP in patients with CDP in terms of safety and efficacy, to evaluate effects of HMP, within 2 months of observation, on cutaneous cell-mediated immunity (CCMI) as well as other basic immune parameters, and the production of interleukin-2 (IL-2) and interleukin-6 (IL-6). Results have shown that HMP does not influence CCMI nor the sieric levels of immunoglobulins or other immune parameters. Furthermore, it also has no effects on the 3rd and 4th complement fractions, on white blood cells count and T-lymphocyte subpopulations, on presence of seric autoantibodies, nor on production of IL-2 and IL-6. Therapy with HMP has not effects on the studied parameters of the immune system and does not seem to have any influence on the immune competence and immune response in patients with chronic pain
CD8 and CD4 lymphocyte subsets, their soluble receptors (sCD8, sCD4) and interleukine-2 soluble receptor (sIL2r) in polymyalgia rheumatica (PMR). A comparison between two steroid treatment (prednisone, PDN and deflazacort, DFZ) and with elderly-onset (EoRA) and adult-onset (AoRA) rheumatoid arthritis in a retrospective study.
No full text
Valutazione ultrasonometrica del picco di massa ossea in giovani donne dell’Italia centrale.
No full text- …
